In a report released yesterday, Liisa Bayko from Evercore ISI maintained a Buy rating on Theravance Biopharma (TBPH – Research Report), with a price target of $14.00. The company's shares closed last Tuesday at $9.19. According to TipRanks.com, Bayko is a 4-star analyst with an average return of 9.1% and a 45.4% success rate. Bayko covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Madrigal Pharmaceuticals, and Crispr Therapeutics AG. Currently, the analyst consensus on Theravance Biopharma is a Hold with an average price target of $11.33, implying a 19.3% upside from current levels. In a report released yesterday, H.C.
https://www.tipranks.com/news/blurbs/theravance-biopharma-tbph-gets-a-buy-rating-from-evercore-isi?utm_source=advfn.com&utm_medium=referral
Theravance Biopharma (NASDAQ:TBPH)
Historical Stock Chart
From Aug 2022 to Sep 2022 Click Here for more Theravance Biopharma Charts.
Theravance Biopharma (NASDAQ:TBPH)
Historical Stock Chart
From Sep 2021 to Sep 2022 Click Here for more Theravance Biopharma Charts.